Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT00409435
PHASE2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
Sponsor: Mayo Clinic
View on ClinicalTrials.gov
Summary
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Official title: Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome
Key Details
Gender
All
Age Range
15 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2006-10
Completion Date
2027-02
Last Updated
2026-03-05
Healthy Volunteers
No
Conditions
Interventions
DRUG
pyridostigmine
one 180 mg capsule per day for 3 days
DRUG
Placebo
one capsule per day for 3 days
Locations (1)
Mayo Clinic
Rochester, Minnesota, United States